Cecilia Pérez Piñero

Cecilia Pérez Piñero

Auto-generated profile, based on publicly available information

Cecilia Pérez Piñero

Instituto de Biología y Medicina Experimental (IBYME), CONICET Buenos Aires Argentina

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2011 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
CPC Pérez Piñero
C Pérez Piñero
ABA Bruzzone
A Bruzzone
MSMg Sarappa
Mg Sarappa
LCLf Castillo
Lf Castillo
ILIa Lüthy
Ia Lüthy
BACKGROUND AND PURPOSE β‐Adrenoceptors are expressed in human and experimental animal breast cancer cells. However, the effect of the agonists and antagonists reported on cell proliferation and tumour growth was paradoxical, precluding their utilization as possible adjuvant therapy, mainly in the cases of refractory tumours.EXPERIMENTAL APPROACH β‐Adrenoceptor expression was analysed by immunofluorescence and RT‐PCR. Cell proliferation was assessed by [3H]‐thymidine incorporation, tumour growth by measuring with a calliper and ERK 1/2 phosphorylation by Western blotting.KEY RESULTS β2‐Adrenoceptor expression was confirmed in the mouse and human cells tested. Cell proliferation was increased by adrenaline (by α2‐adrenoceptor action) and decreased in every tested cell line by the β‐adrenoceptor agonist isoprenaline and the β2‐adrenoceptor agonist salbutamol. Isoprenaline and salbutamol reduced tumour growth in every tumour tested (mouse C4‐HD and CC4‐3‐HI and human IBH‐4, IBH‐6 and MDA‐MB‐231 cell lines growing as xenografts in nude mice). These effects were reversed by the β‐adrenoceptor antagonist propranolol. The α2‐adrenoceptor antagonist rauwolscine and the β2‐adrenoceptor agonist salbutamol were equally effective in diminishing tumour growth. ERK 1/2 activation analysed in IBH‐4 tumours correlated with tumour growth, with the β‐adrenoceptor agonists decreasing its activation. Inhibition of ERK 1/2 phosphorylation in vitro was mainly mediated by the PKA pathway.CONCLUSIONS AND IMPLICATIONS In our experimental models, the β‐adrenoceptor agonists inhibited breast cancer cell proliferation and tumour growth, probably mediated by inhibition of ERK 1/2 phosphorylation. The β‐adrenoceptor agonists were as effective as the α2‐adrenoceptor antagonist rauwolscine, providing possible novel adjuvant treatments for breast cancer.

1 October 2008 in British Journal of Pharmacology
Verified
Journal Article
Closed access
ABA Bruzzone
A Bruzzone
CPC Pérez Piñero
C Pérez Piñero
LCL F Castillo
L F Castillo
MSM G Sarappa
M G Sarappa
PRP Rojas
P Rojas
ILI A Lüthy
I A Lüthy

15 November 2005 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
SVStella Maris Vázquez
Stella Maris Vázquez
AMAlejandro Gustavo Mladovan
Alejandro Gustavo Mladovan
CPCecilia Pérez
Cecilia Pérez
ABAriana Bruzzone
Ariana Bruzzone
ABAlberto Baldi
Alberto Baldi
ILIsabel Alicia Lüthy
Isabel Alicia Lüthy

7 March 2019 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SGSebastián Giulianelli
Sebastián Giulianelli
MRMarina Riggio
Marina Riggio
TGTomas Guillardoy
Tomas Guillardoy
CPCecilia Pérez Piñero
Cecilia Pérez Piñero
MGMaría A. Gorostiaga
María A. Gorostiaga
CLClaudia Lanari
Claudia Lanari
Progression to hormone‐independent growth leading to endocrine therapy resistance occurs in a high proportion of patients with estrogen receptor alpha (ERα) and progesterone receptors (PR) positive breast cancer. We and others have previously shown that estrogen‐ and progestin‐induced tumor growth requires ERα and PR interaction at their target genes. Here, we show that fibroblast growth factor 2 (FGF2)‐induces cell proliferation and tumor growth through hormone‐independent ERα and PR activation and their interaction at the MYC enhancer and proximal promoter. MYC inhibitors, antiestrogens or antiprogestins reverted FGF2‐induced effects. LC–MS/MS identified 700 canonical proteins recruited to MYC regulatory sequences after FGF2 stimulation, 397 of which required active ERα (ERα‐dependent). We identified ERα‐dependent proteins regulating transcription that, after FGF2 treatment, were recruited to the enhancer as well as proteins involved in transcription initiation that were recruited to the proximal promoter. Also, among the ERα‐dependent and independent proteins detected at both sites, PR isoforms A and B as well as the novel protein product PRBΔ4 were found. PRBΔ4 lacks the hormone‐binding domain and was able to induce reporter gene expression from estrogen‐regulated elements and to increase cell proliferation when cells were stimulated with FGF2 but not by progestins. Analysis of the Cancer Genome Atlas data set revealed that PRBΔ4 expression is associated with worse overall survival in luminal breast cancer patients. This discovery provides a new mechanism by which growth factor signaling can engage nonclassical hormone receptor isoforms such as PRBΔ4, which interacts with growth‐factor activated ERα and PR to stimulate MYC gene expression and hence progression to endocrine resistance.

1 May 2009 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ILI A. Luthy
I A. Luthy
ABA. Bruzzone
A. Bruzzone
CPC. Perez Pinero
C. Perez Pinero
LCL. F. Castillo
L. F. Castillo
ICI. J. Chiesa
I. J. Chiesa
MSM. G. Sarappa
M. G. Sarappa
Epinephrine and Norepinephrine, typically released during stress bind to nine different adrenoceptors (AR) which classically control the cardiovascular and respiratory systems. New targets were described for the many agonists and antagonists developed for these AR, as the central nervous system. During the last three decades, AR expression and action on the mammary gland/breast were extensively investigated. In the cow mammary gland, good milkability was associated with low density of β2-AR and high density of α2-AR. In the rat normal mammary gland, β-AR are expressed in the epithelial cells, alveoli, ducts, and adipocytes showing an exquisite regulation by steroid hormones and prolactin. In rat dimethylbenz(a)anthracene (DMBA) tumors, a close correlation was observed between tumor growth and β-AR concentration. β2-AR were described in numerous human cell lines and breast tumors. The action of β-adrenergic compounds on cell proliferation is contradictory. While some authors found that β-agonists significantly inhibit cancer cell proliferation and tumor growth in mice, others described a significant reduction in DNA synthesis by β-blockers. Also, positive effects of β-AR on human carcinoma cell migration have been described. α2-AR are expressed in human breast cancer and non-cancer cell lines, their stimulation being associated with increased cell proliferation. In vivo clonidine increased tumor growth and α2-adrenergic antagonists completely reversed this effect. When administered alone, rauwolscine inhibited tumor growth behaving as an inverse agonist. Therefore, the numerous adrenergic β- and α-AR agonists or antagonists could prove to be unexpected therapeutic options for mammary gland/ breast and mainly breast cancer.

1 July 2011 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
ABA. Bruzzone
A. Bruzzone
CPC. Perez Pinero
C. Perez Pinero
PRP. Rojas
P. Rojas
MRM. Romanato
M. Romanato
HGH. Gass
H. Gass
ILI. A. Luthy
I. A. Luthy
We have previously described enhanced human breast cancer cell proliferation and mouse mammary tumor growth induced by α2-adrenergic agonists, associated with α2-adrenoceptor (α2-AR) expression in epithelial cells. The aim of the present work was to assess if stromal fibroblasts can contribute to this effect. α2-AR expression was assessed by immunocytochemistry and immunohistochemistry, cell proliferation by [3H]- Thymidine incorporation and tumor growth by measuring with caliper. All tested mouse and human fibroblasts expressed at least two α2-AR subtypes and α2-adrenergic agonists enhanced fibroblast proliferation. In vivo, the α2-adrenergic agonist clonidine significantly enhanced tumor growth. The α2- adrenergic antagonist rauwolscine reversed this effect, but when administered alone, significantly inhibited tumor growth. Clonidine significantly stimulated cell proliferation in the epithelial-enriched fraction, the cancer associated fibroblastenriched fraction and the co-culture of both fractions in primary cultures from both tumors (IBH-4 and IBH-6). Rauwolscine reversed clonidine stimulation in every fraction. However, when incubated alone, the inhibitory effect was observed in fractions from IBH-4 tumors but not from IBH-6 tumors. These experiments show that fibroblasts from tumor stroma are also influenced by α2-adrenergic compounds through the α2-ARs expressed in these cells. Moreover, the α2-adrenergic antagonist rauwolscine could eventually block in both epithelial and stromal cells, the mitogenic effect of catecholamines released during stress, providing a potential additional treatment for breast cancer patients. Chemists synthesizing adrenergic compounds should consider their action in breast cancer patients.